Gut microbiome;
Colorectal cancer;
Probiotics;
Omics;
D O I:
10.1007/s12010-021-03498-9
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Dysbiosis of the gut microbiome has been associated with the development of colorectal cancer (CRC). Gut microbiota is involved in the metabolic transformations of dietary components into oncometabolites and tumor-suppressive metabolites that in turn affect CRC development. In a healthy colon, the major of microbial metabolism is saccharolytic fermentation pathways. The alpha-bug hypothesis suggested that oncogenic bacteria such as enterotoxigenic Bacteroides fragilis (ETBF) induce the development of CRC through direct interactions with colonic epithelial cells and alterations of microbiota composition at the colorectal site. Escherichia coli, E. faecalis, F. nucleatum, and Streptococcus gallolyticus showed higher abundance whereas Bifidobacterium, Clostridium, Faecalibacterium, and Roseburia showed reduced abundance in CRC patients. The alterations of gut microbiota may be used as potential therapeutic approaches to prevent or treat CRC. Probiotics such as Lactobacillus and Bifidobacterium inhibit the growth of CRC through inhibiting inflammation and angiogenesis and enhancing the function of the intestinal barrier through the secretion of short-chain fatty acids (SCFAs). Crosstalk between lifestyle, host genetics, and gut microbiota is well documented in the prevention and treatment of CRC. Future studies are required to understand the interaction between gut microbiota and host to the influence and prevention of CRC. However, a better understanding of bacterial dysbiosis in the heterogeneity of CRC tumors should also be considered. Metatranscriptomic and metaproteomic studies are considered a powerful omic tool to understand the anti-cancer properties of certain bacterial strains. The clinical benefits of probiotics in the CRC context remain to be determined. Metagenomic approaches along with metabolomics and immunology will open a new avenue for the treatment of CRC shortly. Dietary interventions may be suitable to modulate the growth of beneficial microbiota in the gut.
机构:
Inst Oncol Ljubljana, Dept Med Oncol, Zaloska 2, SI-1000 Ljubljana, Slovenia
Univ Ljubljana, Fac Med, Ljubljana, SloveniaInst Oncol Ljubljana, Dept Med Oncol, Zaloska 2, SI-1000 Ljubljana, Slovenia
机构:
Amer Univ Sharjah, Coll Arts & Sci, Sharjah 26666, U Arab Emirates
Istinye Univ, Dept Med Biol, Fac Med, TR-34010 Istanbul, TurkeyAmer Univ Sharjah, Coll Arts & Sci, Sharjah 26666, U Arab Emirates
Siddiqui, Ruqaiyyah
论文数: 引用数:
h-index:
机构:
Boghossian, Anania
Alharbi, Ahmad M.
论文数: 0引用数: 0
h-index: 0
机构:
Taif Univ, Dept Clin Lab Sci, Coll Appl Med Sci, Taif 21944, Saudi ArabiaAmer Univ Sharjah, Coll Arts & Sci, Sharjah 26666, U Arab Emirates
Alharbi, Ahmad M.
Alfahemi, Hasan
论文数: 0引用数: 0
h-index: 0
机构:
Al Baha Univ, Dept Med Microbiol, Fac Med, Al Baha 65799, Saudi ArabiaAmer Univ Sharjah, Coll Arts & Sci, Sharjah 26666, U Arab Emirates
Alfahemi, Hasan
Khan, Naveed Ahmed
论文数: 0引用数: 0
h-index: 0
机构:
Istinye Univ, Dept Med Biol, Fac Med, TR-34010 Istanbul, Turkey
Univ Sharjah, Dept Clin Sci, Coll Med, Sharjah 27272, U Arab EmiratesAmer Univ Sharjah, Coll Arts & Sci, Sharjah 26666, U Arab Emirates
机构:
China Med Univ, Sch Basic Med Sci, Dept Pathogen Biol, Shenyang, Peoples R China
China Med Univ, Dept Clin Med, Shenyang, Peoples R ChinaChina Med Univ, Sch Basic Med Sci, Dept Pathogen Biol, Shenyang, Peoples R China
Ma, Junting
Zhu, Wenwen
论文数: 0引用数: 0
h-index: 0
机构:
China Med Univ, Sch Basic Med Sci, Dept Pathogen Biol, Shenyang, Peoples R ChinaChina Med Univ, Sch Basic Med Sci, Dept Pathogen Biol, Shenyang, Peoples R China
Zhu, Wenwen
Liu, Beixing
论文数: 0引用数: 0
h-index: 0
机构:
China Med Univ, Sch Basic Med Sci, Dept Pathogen Biol, Shenyang, Peoples R ChinaChina Med Univ, Sch Basic Med Sci, Dept Pathogen Biol, Shenyang, Peoples R China